Arrowhead Shares Rise After Alzheimer’s Drug Trial Data

Arrowhead Pharmaceuticals shares gained more than 4% in premarket trading Wednesday, Oct. 14, after the company declared initial clinical validation of its TRiM delivery platform based on early-stage trial data for its experimental Alzheimer’s therapy, ARO-MAPT. ARO-MAPT is an RNA interference therapy. Arrowhead’s validation statement reflects the company’s assessment of the trial data. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.